--- title: "The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range" type: "News" locale: "en" url: "https://longbridge.com/en/news/284896142.md" description: "Seaport Therapeutics (SPTX), a Boston-based biotech, has increased its IPO size to 14.16 million shares, priced at $18.00, raising $254.88 million. The shares will begin trading on NASDAQ on May 1, 2026. The company plans to use the proceeds for Phase 2 clinical trials of its drugs for major depression. At pricing, Seaport Therapeutics has a market cap of $954.5 million. Goldman Sachs and others are the joint book-runners for the IPO." datetime: "2026-05-01T12:00:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284896142.md) - [en](https://longbridge.com/en/news/284896142.md) - [zh-HK](https://longbridge.com/zh-HK/news/284896142.md) --- # The IPO Buzz: Seaport Therapeutics Increases IPO’s Size & Prices it at $18 – Top of Range **Seaport Therapeutics (SPTX), a Boston-based biotech developing drugs to treat major depression, increased its IPO’s size at pricing – to 14.16 million shares – up from 11.8 million in the prospectus – and priced its IPO at $18.00 – the top of its range – to raise $254.88 million on Thursday night, April 30, 2026.** **Shares of Seaport Therapeutics are set to start trading today – Friday, May 1, 2026 – on the NASDAQ.** **Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel are the joint book-runners.** **At pricing, Seaport Therapeutics had a market cap of $954.5 million.** **Seaport Therapeutics (SPTX) intends to use the IPO’s proceeds to help fund the Phase 2 clinical trials of its leading drug candidates, GlyphAllo (SPT-300) and GlyphAgo (SPT-320), to treat major depression, including postpartum depression.** **The company is not profitable.** **(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)** **Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.** **To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.** **Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.** ### Related Stocks - [SEELQ.US](https://longbridge.com/en/quote/SEELQ.US.md) - [SEEL.US](https://longbridge.com/en/quote/SEEL.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [SF.US](https://longbridge.com/en/quote/SF.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md) - [SFB.US](https://longbridge.com/en/quote/SFB.US.md) - [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md) - [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md) ## Related News & Research - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)